Drug intelligence / Profile preview

RTX-300

Development stage: Preclinical
Lead developer: Resonant Therapeutics
Administration: Intraarticular, Intravesical, Epidural, Intrathecal

Overview

RTX-300 is a drug initially developed by Resonant Therapeutics, Inc. It is currently in preclinical development. Its therapeutic areas include neoplasms, skin and musculoskeletal diseases, and urogenital diseases, with active indications for breast cancer and prostatic cancer.

Beyond the preview

Go deeper on RTX-300.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RTX-300.

Explore the full profile